TorbicH, KrishnanS, HarnegieMP, DuggalA. Neuromuscular blocking agents for ARDS: a systematic review and meta-analysis. Respir Care, 2021; 66(1):120–128.
2.
SlutskyAS. Neuromuscular blocking agents in ARDS. N Engl J Med, 2010; 363(12):1176–1180.
3.
GattinoniL, MariniJJ. Prone positioning and neuromuscular blocking agents are part of standard care in severe ARDS patients: we are not sure. Intensive Care Med, 2015; 41(12):2201–2203.
4.
HraiechS, ForelJM, PapazianL. The role of neuromuscular blockers in ARDS: benefits and risks. Curr Opin Crit Care, 2012; 18(5):495–502.
AndradeC. The use and limitations of the fragility index in the interpretation of clinical trial findings. J Clin Psychiatry, 2020; 81(2):20f13334.
7.
RidgeonEE, YoungPJ, BellomoR, MucchettiM, LemboR, LandoniG. The fragility index in multicenter randomized controlled critical care crials. Crit Care Med, 2016; 44(7):1278–1284.
MurrayMJ, DeBlockH, ErstadB, GrayA, JacobiJ, JordanC, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med, 2016; 44(11):2079–2103.
10.
PapazianL, AubronC, BrochardL, ChicheJD, CombesA, DreyfussD, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care, 2019; 9(1):69.
11.
CalfeeCS, DelucchiK, ParsonsPE, ThompsonBT, WareLB, MatthayMA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med, 2014; 2(8):611–620.
12.
CalfeeCS, DelucchiKL, SinhaP, MatthayMA, HackettJ, Shankar-HariM, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med, 2018; 6(9):691–698.
